-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

Benzinga·06/26/2026 12:48:36
Listen to the news
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.